MONTREAL, May 11, 2015 /PRNewswire/ - H&P Labs Inc. today announced it has been awarded a non-refundable contribution of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program ("NRC-IRAP").
This investment will support the development of new antivirals to fight viral infections such as Ebola, Lassa Fever and Chikungunya.
"The development of new antivirals is in line with our strategy to expand our product portfolio and continue to develop treatment options against life-threatening viruses," said John Huss, President and CEO of H&P Labs Inc. "We would sincerely like to thank NRC for their continued support and encouragement of H&P Labs."
About H&P Labs:
H&P Labs is a private biotechnology company focused on the development of drugs to fight infectious viral diseases worldwide for public health and biodefense missions. H&P Labs' objective is to deliver treatment options against Viral Hemorrhagic Fevers (VHFs), such as Ebola, Lassa, Dengue, as well as other important and often life-threatening viruses (e.g., MERS, Chikungunya, EEE/WEE/VEE).
SOURCE H&P Labs
Help employers find you! Check out all the jobs and post your resume.